Liraglutide
Fat LossFDA-approved daily GLP-1 agonistEstablished
FDA-approved once-daily GLP-1 receptor agonist for type 2 diabetes (Victoza, up to 1.8 mg) and chronic weight management (Saxenda, up to 3 mg).
For research use only.
Key Facts
- CAS
- 204656-20-2
- Molecular Weight (MW)
- 3751.2 g/mol
- Half-life
- ~13 hours
- Unit
- mg
- Administration Route
- Subcutaneous
- Frequency
- Once daily
- Last updated
- 8/23/2026
- Targets
- GLP-1 receptor
Overview
FDA-approved once-daily GLP-1 receptor agonist for type 2 diabetes (Victoza, up to 1.8 mg) and chronic weight management (Saxenda, up to 3 mg).
Protocol
- Dosage Range
- Saxenda 0.6→3.0 mg daily; Victoza 0.6→1.8 mg daily
- Frequency
- Once daily
- Cycle
- Long-term as prescribed
- Administration Route
- Subcutaneous
- Reconstitution Guide
- Prefilled pen — no reconstitution
Science
Mechanism of Action
Acylated GLP-1 analog that binds albumin, extending half-life to allow once-daily dosing. Improves glucose-dependent insulin secretion and reduces appetite.
Targets
GLP-1 receptor
Studies
- LEADER CVOT— Journal/year not available
- SCALE obesity— Journal/year not available
Benefits
Labeled T2D and obesity therapyCV outcome data (Victoza)
Potential Side Effects
- Nausea
- Vomiting
- Diarrhea
- Gallbladder events
References
- Saxenda labelExternal link · Year —
- LEADER PMID 27295427External link · Year —